Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | BTK del |
Therapy | Edralbrutinib |
Indication/Tumor Type | mantle cell lymphoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BTK del | mantle cell lymphoma | predicted - resistant | Edralbrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, Edralbrutinib (TG-1701) treatment resulted in reduced cell growth inhibition in a mantle cell lymphoma cell line with BTK knockout compared to the parental wild-type BTK cell line in culture (PMID: 34551904). | 34551904 |
PubMed Id | Reference Title | Details |
---|---|---|
(34551904) | Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma. | Full reference... |